- Home
- / Orchestra BioMed
Orchestra BioMed
Stock Price
$6.1
2024-10-29
Market Capitalization
$231.9 M
2024-10-29
Revenue
$33.5 M
FY, 2025
Orchestra BioMed Summary
Company Summary
- Overview
- Orchestra BioMed (also known as Orchestra BioMed Holdings and formerly as Health Sciences Acquisitions Corporation 2 and Orchestra BioMed) is a biomedical company that develops therapeutic products for procedure-based medicine. It focuses on the artery disease and hypertension markets.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- New Hope, PA, US | view all locations
- Cybersecurity rating
Table of Contents
Key People
Jason Aryeh, Director
Darren R. Sherman, President, COO, Director and Founder
Yuval Mika, General Manager and Chief Technology Officer, Bioelectronic Therapies
LocationsView all
1 location detected
New Hope, PA HQ
United States
150 Union Square Dr
Orchestra BioMed Financials
Summary Financials
- Revenue (Q1, 2026)
- $110.0K
- Gross profit (Q1, 2026)
- $78.0K
- Net income (Q1, 2026)
- ($20.7M)
- Cash (Q1, 2026)
- $28.4M
- EBIT (Q1, 2026)
- ($22.1M)
- Enterprise value
- $219.3M